touchMDT

Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes

Access to this content is not permitted for healthcare professionals based in the US.

Back to Education
Gynaecological Oncology Watch Time: 38 mins

touchMDT Investigating immunotherapies for endometrial cancer: Working as a MDT to identify patients and improve outcomes

Select a discussion in the hub to watch our multidisciplinary faculty share their expert perspectives on the potential of immunotherapies to improve the management of patients with endometrial cancer.

Overview & Learning Objectives

A MDT discusses a 62-year-old female with recurrent, advanced-stage EC.
What clinical factors guide treatment?

Gynaecological Oncologist & Medical Oncologist

A gynaecological oncologist and a medical oncologist discuss the latest data on PD-1/PD-L1 inhibitors and what they mean for patients with EC.

Expert Spotlight
Prof. N Concin
Evang. Kliniken Essen-Mitte, Essen, Germany
Innsbruck Medical University, Innsbruck, Austria
Dr A González-Martín
Clínica Universidad de Navarra, Madrid, Spain

A gynaecological oncologist and a medical oncologist review the latest immunotherapy data in EC.

Listen on the go

Learn more Back to MDT Hub Time: 12:23
 
Gynaecological Oncologist, Medical Oncologist & Pathologist

A gynaecological oncologist, a medical oncologist and a pathologist, as a multidisciplinary tumour board, review a patient profile and describe how they would determine suitability for PD-1/PD-L1 inhibitor therapy.

Expert Spotlight
Prof. N Concin
Evang. Kliniken Essen-Mitte, Essen, Germany
Innsbruck Medical University, Innsbruck, Austria
Dr A González-Martín
Clínica Universidad de Navarra, Madrid, Spain
Dr A León-Castillo
Netherlands Cancer Institute, Amsterdam, The Netherlands

The MDT tumour board discusses a patient with EC and key considerations that guide treatment.

Listen on the go

Learn more Back to MDT Hub Time: 13:55
 
Gynaecological Oncologist & Pathologist

A gynaecological oncologist and a pathologist discuss how patients with EC should be tested to determine suitability for PD-1/PD-L1 inhibitor therapy.

Expert Spotlight
Prof. N Concin
Evang. Kliniken Essen-Mitte, Essen, Germany
Innsbruck Medical University, Innsbruck, Austria
Dr A León-Castillo
Netherlands Cancer Institute, Amsterdam, The Netherlands

A gynaecological oncologist and a pathologist discuss recommendations for biomarker testing.

Listen on the go

Learn more Back to MDT Hub Time: 12:16
 
Back To Top
Overview & Learning Objectives
Overview

Join our endometrial cancer (EC) multidisciplinary team as they discuss the latest developments in an exciting era of patient management with PD-1/PD-L1 inhibitors, including important clinical considerations and testing to identify the patients who are most likely to benefit from immunotherapy.

Learning Objectives

After watching this activity, participants should be better able to:

  • Evaluate the latest data for PD-1/PD-L1 inhibitors in the treatment of EC
  • Identify which patients with EC may benefit from treatment with PD-1 inhibitors
  • Summarize the appropriate testing used to assess whether PD-1 inhibitors maybe suitable for patients with EC
Faculty & Disclosures
Prof. Nicole Concin

Evang. Kliniken Essen-Mitte, Essen, Germany
Innsbruck Medical University, Innsbruck, Austria

Prof. Nicole Concin is Consultant Gynaecological Oncologist at Evang. Kliniken Essen-Mitte, Essen, Germany, and Professor of Experimental Gynaecology at Innsbruck Medical University, Innsbruck, Austria. She is currently the president elect of the European Society of Gynaecological Oncology, coordinator of the FP7 European project GANNET53 (Ganetespib in metastatic, p53-mutant ovarian cancer) and co-chair of the European Network for Gynaecological Oncological Trial (ENGOT) Early Drug Development Network. She has over 100 publications in gynaecological oncology and has been active in the development of guidelines for the management of patients with endometrial carcinoma.

Prof. Nicole Concin discloses: Consulting/advisory fees from Akesobio, AstraZeneca, Ensai, eTheRNA Immunotherapies NV, GlaxoSmithKline, Mersana and Seattle Genetics; Travel expenses from Amgen, Genab and Roche; and Educational activity fees from Medscape Oncology and Merck Sharp & Dohme.

 

Dr Antonio González-Martín

Clínica Universidad de Navarra, Madrid, Spain

Antonio González-Martín, MD, PhD, is currently the director of the Cancer Centre Universidad de Navarra in Spain. He is also an associate professor of medicine at Francisco de Vitoria University in Madrid, Spain, where he obtained his PhD. read more

Dr González-Martín specializes in the treatment of gynaecological and breast cancer. He is the chairman of the Spanish Ovarian Cancer Research Group (GEICO), the GEICO representative in the European Network for Gynecological Oncological Trials (ENGOT), and one of the representatives of GEICO in the Gynecologic Cancer InterGroup (GCIG). He also served as the chair of the ovarian cancer committee in GCIG for the period 2016–2020, and as the chairman of ENGOT for the period 2018–2020. In addition, Dr González-Martín is a member of the board of the Spanish Society of Medical Oncology (SEOM) and he is also Associate Editor of the International Journal of Gynecological Cancer.

Dr González-Martín has numerous relevant publications in the field of gynaecological and breast cancer.

Dr Antonio González-Martín discloses: Consulting/advisory fees from Amgen, AstraZeneca, Clovis, Genab, Mersana and Roche; Speakers’ bureau fees from AstraZeneca, Clovis, GlaxoSmithKline, Merck Sharp & Dohme and Roche; Research funding from GlaxoSmithKline and Roche; and Travel, accommodations or expenses from AstraZeneca, GlaxoSmithKline and Roche.

Dr Alicia León-Castillo

Netherlands Cancer Institute, Amsterdam, The Netherlands

Alicia León-Castillo was born in Santander, Spain, and received her MD degree from the University of Cantabria, where she also did her Anatomic Pathology Residency. read more

After completing her residency, she pursued a PhD in molecular tumour pathology at Leiden University, focusing on the molecular classification of endometrial cancer. Under the mentorship of Drs Vincent Smit, Carien Creutzberg and Tjalling Bosse, she addressed outstanding issues encountered when interpreting p53 and mismatch repair protein immunohistochemistry stains and POLE exonuclease domain sequencing in endometrial cancers, in order to allow for the assignment of molecular subgroups on individual cases. Within the TransPORTEC consortium, she analyzed the prognostic and predictive value of the molecular classification on patients with high-risk endometrial cancer.

Dr León-Castillo now works in the department of pathology of Antoni van Leeuwenhoek, Netherlands Cancer Institute, in Amsterdam, the Netherlands.

Dr Alicia León-Castillo discloses: no financial interests/relationships or affiliations in relation to this activity.

Downloads

View and download resources from this activity to support your learning and share with colleagues

Register to touchONCOLOGY for FREE
  • Peer-reviewed journals and expert opinions
  • Interactive CME and e-learning modules
  • Video conference highlights
Feedback Close
Feedback

Please provide feedback for this touchMDT on the following
(scale 1-5, 1 strongly disagree; 5 strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72